Recent studies have converged on the intersection of GLP|GIP|glucagon receptor stimulant therapies and dopaminergic communication. While GIP agonists are commonly employed for managing type 2 diabetes mellitus, their unexpected impacts on reinforcement circuits, specifically influenced by dopaminergic systems, are gaining considerable attention. Th